Cancer News: Bladder
Pembrolizumab, an immunotherapy agent, has been approved for some types of locally advanced or metastatic bladder cancer.
Immune check point inhibitors seem to be the suitable treatment for chemotherapy-ineligible patients with metastatic bladder cancer.
Treating metastatic bladder cancer patients with Tecentriq resulted in tumor shrinkage with less toxic effects, researchers say.
US regulators approved the PD-L1 inhibitor atezolizumab for the treatment of advanced urothelial cancer, the most common form of bladder cancer.
Bladder cancer patients who underwent surgery were found to be at risk due to blood clots formed in their vein after hospital discharge.
Advanced urothelial cancer patients treated with ramucirumab plus docetaxel as second-line treatment reduced disease progression risk, a new study shows.
AstraZeneca‘s new drug durvalumab brings hope to bladder cancer patients receiving breakthrough therapy designation by the US FDA.
Patients with locally advanced bladder cancer lived longer when treated with adjuvant chemotherapy following cystectomy, a new large study shows.
Focusing on patient-reported health status, scientists reported that the mental health of a bladder cancer patient prior to surgery affects postoperative outcomes.
Investigational immunotherapy increased overall survival in patients with metastatic bladder cancer, according to a new study.
An investigational immunotherapy appears effective in treating patients with metastatic urothelial cancer, two recent trials report.
Roche’s new immune-system boosting drug, atezolizumab, improved patient outcomes for lung and bladder cancer patients, according to separate phase 2 trials.
Bladder cancer patients treated with robot-assisted surgery showed similar beneficial results to those who underwent a traditional open operation, a new study suggests.
Taking chemotherapy after surgery was found to improve overall survival in bladder cancer patients.
Outcomes after laparoscopic surgery for bladder cancer patients are comparable to open surgery: after 5 years, 66% of patients had no signs of recurrence.
Scientists have developed a breakthrough new treatment for advanced bladder cancer, a type which has not seen major treatment advances in the last 30 years.
New research found that invisible blood in urine may be an early warning sign of bladder cancer. This may shape guidelines for how doctors diagnose the disease.
Patients with bladder cancer are two times more likely to have complications after a radical cystectomy procedure if they have a biomarker for poor nutritional status before the operation, according to study findings presented at the 2013 Clinical Congress of the American College of Surgeons. Surgeons from the University of North Carolina School of Medicine, Chapel Hill, identified a potentially modifiable risk factor for such postsurgical problems: a low preoperative level of albumin, a marker of the protein level in the blood.
An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer. Their findings are reported online in Nature Genetics.
Men who continued to smoke after a cancer diagnosis had an increased risk of death compared with those who quit smoking after diagnosis, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Radiation therapy against endometrial cancer linked to increased risk of bladder cancer later in life
Radiation therapy for uterine (endometrial) cancer may increase a patient's risk of developing bladder cancer.
Lung and bladder cancer biomarker analysis have similar genetic abnormalities. This latest research may have diagnostic, prognostic and treatment implications.
A new discovery showed that invasive bladder cancer and some breast cancers have genetic similarities. This could lead to new therapies and diagnostic aids.
A new licensing agreement will bring to the market a new test for early detection of prostate and bladder cancers. The test is based on the EN2 biomarker.
A patient with advanced bladder cancer and rare genetic mutations experienced complete response for 14 months to the drug combination everolimus and pazopanib.
Although treatment guidelines for high-risk bladder cancer include chemotherapy before or after surgery, it is not commonly used in routine clinical practice.
A phase 1 study for an advanced bladder cancer drug showed promising results in patients with certain tumor types who did not respond to other treatments.